Company Filing History:
1 out of 1,627 
1 out of 328 
1 out of 7 Years Active: 2010
Title: Innovations of John Schmieg in Vaccine Development
Introduction
John Schmieg is an accomplished inventor based in New York, NY, known for his significant contributions to the field of immunology. He holds a patent that focuses on enhancing the effectiveness of vaccines against cancer and infectious diseases. His work is pivotal in the ongoing quest to improve vaccine efficacy and patient outcomes.
Latest Patents
John Schmieg's notable patent is titled "Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases." This invention relates to methods and compositions designed to augment the immunogenicity of an antigen in mammals. The patent describes the administration of an antigen alongside an adjuvant composition that includes a synthetic glycolipid compound. The innovative aspect of this invention lies in its ability to enhance and extend antigen-specific Th1-type responses, particularly CD8+ T cell responses. This advancement has potential applications in the prophylaxis and treatment of various infectious and neoplastic diseases.
Career Highlights
Throughout his career, John Schmieg has worked with prestigious institutions such as New York University and the City University of New York. His research and innovations have made a significant impact on the scientific community, particularly in the field of vaccine development.
Collaborations
John has collaborated with notable colleagues, including Moriya Tsuji and Richard W. Franck. Their combined expertise has contributed to the advancement of research in immunology and vaccine efficacy.
Conclusion
John Schmieg's innovative work in vaccine development showcases the importance of scientific research in combating diseases. His patent on synthetic glycolipids as adjuvants represents a significant step forward in enhancing vaccine effectiveness.